Cel-Sci Corporation Common Stock (CVM)
Stock · AMEX · Health Care
$1.76as of 10/16/2026
Price chart
Active signals
CVM Signal Track Record
How signals performed across all stocks →What CVM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -10.9% | 27% | September 30, 2026 |
| Bollinger Band Breakdown | 22 | -4.5% | 36% | June 11, 2026 |
| Bollinger Band Breakout | 20 | -19.8% | 35% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -17.0% | 25% | November 26, 2025 |
| Any 20-session window (baseline) | -7.1% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technol…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Website
- cel-sci.com/
Fundamentals
- 1-day range
- $1.75$1.93
- Market cap
- $28.14M
- P/E (trailing)
- —
- P/E (forward)
- -0.28
- EPS (trailing)
- $-2.68
- Dividend yield
- —
- Beta
- 0.62
- Avg. volume
- 211.1K
- Ex-dividend date
- August 28, 1996
- Dividend pay date
- June 15, 2017
Forecasts
2 analyst ratings
Cel-Sci Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- CVMCel-Sci Corporation Common Stock$1.79▲ 2.87%Market cap $28.14MP/E —$0.89$10.24
- QNCXQuince Therapeutics Inc. Common Stock$32.03▼ 3.61%Market cap $30.04MP/E —$15.1$910
- EVAXEvaxion A/S American Depositary Share$2.83▲ 1.07%Market cap $24.98MP/E —$2.72$12.15
- ESLAEstrella Immunopharma Inc. Common Stock$0.43▼ 19.63%Market cap $32.10MP/E —$0.295$3.15
- ENGNWenGene Therapeutics Inc. Warrants$0.17▲ 1.19%Market cap $33.75MP/E —$0.1113$4.2
- GRMLGreenland Mines Ltd. Common Stock$6▼ 13.79%Market cap $22.19MP/E —$2.82$27.48
- ALGSAligos Therapeutics Inc. Common Stock$4.86▼ 9.83%Market cap $34.10MP/E —$3.98$13.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CVM Cel-Sci Corporation Common Stock | $28.14M | — | $1.79 | ▲ 2.87% | $0.89$10.24 |
| QNCX Quince Therapeutics Inc. Common Stock | $30.04M | — | $32.03 | ▼ 3.61% | $15.1$910 |
| EVAX Evaxion A/S American Depositary Share | $24.98M | — | $2.83 | ▲ 1.07% | $2.72$12.15 |
| ESLA Estrella Immunopharma Inc. Common Stock | $32.10M | — | $0.43 | ▼ 19.63% | $0.295$3.15 |
| ENGNW enGene Therapeutics Inc. Warrants | $33.75M | — | $0.17 | ▲ 1.19% | $0.1113$4.2 |
| GRML Greenland Mines Ltd. Common Stock | $22.19M | — | $6 | ▼ 13.79% | $2.82$27.48 |
| ALGS Aligos Therapeutics Inc. Common Stock | $34.10M | — | $4.86 | ▼ 9.83% | $3.98$13.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.ChartMill · 10/7/2026
- What's going on in today's sessionChartMill · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 10/7/2026
- CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologyYahoo · 9/15/2026
Insider Activity
Insider Actions →- TALOR EYAL · September 30, 2026 · Grant1.2K @ $2.06
- PRICHEP PATRICIA B · September 30, 2026 · Grant2.1K @ $2.06
- KERSTEN GEERT R · September 30, 2026 · Grant2.6K @ $2.06
- KERSTEN GEERT R · August 25, 2026 · Buy100.0K @ $1.38
- BAILLAVOINE BRUNO JEAN-MARIE · August 14, 2026 · Grant110.0K @ $0.01
- Watson Robert Eugene · August 14, 2026 · Grant110.0K @ $0.01
- CIPRIANO JOHN · August 14, 2026 · Grant80.0K @ $0.01
- TALOR EYAL · August 14, 2026 · Grant250.0K @ $0.01
- PRICHEP PATRICIA B · August 14, 2026 · Grant225.0K @ $0.01
- KERSTEN GEERT R · August 14, 2026 · Grant300.0K @ $0.01
- TALOR EYAL · June 30, 2026 · Grant2.3K @ $1.04
- PRICHEP PATRICIA B · June 30, 2026 · Grant4.1K @ $1.04
- KERSTEN GEERT R · June 30, 2026 · Grant5.2K @ $1.04
- KERSTEN GEERT R · May 14, 2026 · Buy300.0K @ $1.2
- KERSTEN GEERT R · May 13, 2026 · Buy100.0K @ $1.19
Institutional Ownership
March 31, 2026
- Total shares held
- 696.6K
- Total value held
- $2.24M
- Institutional holders
- 35
- Unknown243.6K
- Unknown91.3K
- Unknown85.3K
- Unknown43.3K
- Unknown41.0K
- Unknown35.9K
- Unknown29.9K
- Unknown27.3K
- Unknown22.6K
- Unknown18.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Cel-Sci stock shows high RSI and revenue divergence
Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.
Cel-Sci stock shows high RSI and revenue divergence. Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.